Is Alkem Laboratories Ltd (ALKEM) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Alkem Laboratories Ltd is a good quality company .

Is Alkem Laboratories Ltd (ALKEM) undervalued or overvalued?

The key valuation ratios of Alkem Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Alkem Laboratories Ltd (ALKEM) share price return in the past 10 years?

Alkem Laboratories Ltd share price has appreciated 15.9% annually (CAGR) over the past ten years.

Is Alkem Laboratories Ltd (ALKEM) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Alkem Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Alkem Laboratories Ltd (ALKEM)?

Company share prices are keep on changing according to the market conditions. The current trading price of Alkem Laboratories Ltd (ALKEM) on 17-Apr-2026 16:59:59 at 16:59 is 5583.70.

What is the P/E ratio of Alkem Laboratories?

The latest standalone P/E ratio of Alkem Laboratories as of 17-Apr-2026 is 30.43.

What is the P/B ratio of Alkem Laboratories Ltd (ALKEM)?

The latest standalone P/B ratio of Alkem Laboratories Ltd (ALKEM) as of 17-Apr-2026 is 4.67.

What is the 52-week high and low of Alkem Laboratories Ltd (ALKEM)?

The 52-week high of Alkem Laboratories Ltd (ALKEM) is Rs. 5933.00 and the 52-week low is Rs. 4716.75.

Alkem Laboratories Ltd (ALKEM) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Alkem Laboratories Ltd (ALKEM)
Brand: Alkem Laboratories

Key Metrics

Market Cap

₹66,762 Cr.

P/E Ratio

30.43

Price to Book (P/B)

4.67

Price to Sales (P/S)

7.06

EV/EBITDA

23.38

Return on Capital Employed (ROCE)

19.66%

Current Price

₹5,583.7

Return on Equity (ROE)

18.27%

Return on Assets (ROA)

15.53%

Operating Profit Margin

24.5%

Net Profit Margin

23.71%

Gross Profit Margin

28.7%

Book Value per Share

₹1,194.9

Sales Growth (YoY)

10.67%

Sales Growth (3 Years)

-0.06%

Operating Profit Growth (1 Year)

29.02%

Operating Profit Growth (3 Years)

Net Profit Growth (1 Year)

33.91%

52-Week Low / High

₹4,717 / 5,933

Net Profit Growth (3 Years)

10.68%

Dividend Yield

0.92%

Promoter Holding

51.20%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Revenue growth of Alkem Laboratories Ltd?

Alkem Laboratories Ltd revenue growth is 10.7% for FY-2025 , which is above its 5 year CAGR of 5.7% , indicating faster growth.

Q.1 Promoter shareholding and pledge status of Alkem Laboratories Ltd?

Promoters hold 51.20% of the Alkem Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Alkem Laboratories Ltd vs industry peers?

Alkem Laboratories Ltd revenue CAGR is 5.71% , compared to the industry median CAGR of 8.87% , indicating slower growth and losing its market share.

Q.1 Which industry/sub-sector does Alkem Laboratories Ltd belong to?

Alkem Laboratories Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Stock return of Alkem Laboratories Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 15.4% based on the current price.

DeciZen - make an informed investing decision on Alkem Laboratories

Based on:

Data

Overall Rating ⓘ
Login to view analysis.

1. Quality

2. Valuation

3. Price Trend

Alkem Laboratories stock performance

Key Ratios

Is Alkem Laboratories Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	21.9%	21%	19%	17.1%	20.5%	23.4%	18%	13.2%	15.2%	19.7%	-
Value Creation Index ⓘ	0.6	0.9	0.7	0.5	0.8	1.1	0.6	0.2	0.4	0.8	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	3,859	4,548	5,281	5,714	6,677	7,220	8,830	9,055	7,964	8,813	9,450
Sales YoY Gr.	-	17.9%	16.1%	8.2%	16.9%	8.1%	22.3%	2.6%	-12.1%	10.7%	-
Adj EPS ⓘ	59.2	73.8	60.3	65.7	104.5	138	126.8	93.1	132.2	170.9	183.5
YoY Gr.	-	24.7%	-18.3%	9%	59%	32%	-8.1%	-26.6%	42%	29.2%	-
BVPS (₹) ⓘ	301.1	367.4	408.7	457.2	525.3	637.9	731.4	782.1	882.9	1,030.7	1,194.9
Adj Net Profit ⓘ	708	883	721	786	1,250	1,650	1,516	1,113	1,581	2,043	2,194
Cash Flow from Ops. ⓘ	630	499	318	745	682	1,324	1,299	1,437	1,687	2,189	-
Debt/CF from Ops. ⓘ	0.6	0.7	1.7	0.7	1.8	1	1.7	0.8	0.6	0.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	9.6%	5.7%	-0.1%	10.7%
Adj EPS ⓘ	12.5%	10.3%	10.5%	29.2%
BVPSⓘ	14.7%	14.4%	12.1%	16.7%
Share Price	15.9%	14.9%	18.4%	12.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	21.1	22.1	15.5	15.2	21.3	23.7	18.5	12.3	15.9	17.9	16.5
Op. Profit Mgn % ⓘ	19	19.3	18.9	18.4	22.2	27	20.5	15.3	21	24.5	25.2
Net Profit Mgn % ⓘ	18.4	19.4	13.7	13.8	18.7	22.9	17.2	12.3	19.9	23.2	23.2
Debt to Equity ⓘ	0.1	0.1	0.1	0.1	0.2	0.2	0.3	0.1	0.1	0	-
Working Cap Days ⓘ	180	155	162	159	156	175	178	184	255	264	148
Cash Conv. Cycle ⓘ	41	41	45	51	62	76	80	81	75	46	94

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	183.5	198.3
TTM Sales (₹ Cr.)	9,450	14,253
BVPS (₹) ⓘ	1,194.9	1,170.9
Reserves (₹ Cr.) ⓘ	14,263	13,976
P/BV ⓘ	4.67	4.77
PE ⓘ	30.43	28.16

From the Market
52 Week Low / High (₹)	4716.75 / 5933.00
All Time Low / High (₹)	1175.00 / 6440.00
Market Cap (₹ Cr.)	66,762
Equity (₹ Cr.)	23.9
Face Value (₹)	2
Industry PE ⓘ	42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Alkem Laboratories - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	3,859	4,548	5,281	5,714	6,677	7,220	8,830	9,055	7,964	8,813
Operating Expenses ⓘ +	3,139	3,670	4,308	4,668	5,209	5,271	7,019	7,678	6,293	6,657
Manufacturing Costs	495	654	686	651	704	737	1,081	951	883	986
Material Costs	1,281	1,438	1,739	1,991	2,229	2,308	3,014	3,367	2,080	2,257
Employee Cost	627	722	862	960	1,067	1,159	1,434	1,516	1,478	1,631
Other Costs ⓘ	735	855	1,021	1,067	1,209	1,066	1,490	1,843	1,852	1,784
Operating Profit ⓘ	720	878	973	1,046	1,468	1,949	1,810	1,377	1,671	2,156
Operating Profit Margin (%)	18.7%	19.3%	18.4%	18.3%	22.0%	27.0%	20.5%	15.2%	21.0%	24.5%
Other Income ⓘ +	251	117	101	68	96	190	200	266	306	507
Exceptional Items ⓘ	0	0	0	0	0	-13	0	0	-64	0
Interest ⓘ	59	24	32	28	39	43	38	86	80	76
Depreciation ⓘ	74	76	108	141	187	199	219	230	239	284
Profit Before Tax ⓘ	839	894	934	944	1,338	1,884	1,753	1,327	1,594	2,304
Tax ⓘ	139	11	218	144	74	199	212	193	34	214
Profit After Tax	700	883	716	800	1,264	1,685	1,541	1,134	1,561	2,090
PAT Margin (%)	18.2%	19.4%	13.6%	14.0%	18.9%	23.3%	17.5%	12.5%	19.6%	23.7%
Adjusted EPS (₹)	58.6	73.9	59.9	66.9	105.8	141.0	128.9	94.9	130.5	174.8
Dividend Payout Ratio (%)	22%	20%	22%	24%	24%	21%	26%	53%	31%	26%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	3,600	4,393	4,885	5,465	6,280	7,626	8,744	9,350	10,555	12,322
Share Capital ⓘ	24	24	24	24	24	24	24	24	24	24
Reserves ⓘ	3,576	4,369	4,861	5,441	6,257	7,602	8,720	9,326	10,531	12,298
Debt +	351	368	548	503	1,209	1,333	2,246	1,126	957	371
Long Term Debt	0	0	6	6	6	0	0	0	0	0
Short Term Debt	351	368	541	497	1,203	1,333	2,246	1,126	957	371
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	467	685	819	754	812	953	1,111	1,076	1,571	1,464
Others Liabilities ⓘ	-4	-139	-15	-67	-15	-93	20	94	-332	10
Total Liabilities ⓘ	4,413	5,307	6,236	6,656	8,287	9,818	12,120	11,646	12,751	14,166
Fixed Assets
Net Fixed Assets ⓘ +	875	1,126	1,471	1,606	1,837	1,758	1,882	1,825	1,782	1,591
Gross Block	945	1,263	1,714	1,973	2,352	2,457	2,827	2,932	3,144	3,083
Accumulated Depreciation	70	137	243	367	515	699	945	1,107	1,362	1,492
CWIP ⓘ	147	218	299	382	314	323	232	229	91	77
Investments ⓘ	1,158	1,518	1,545	1,696	1,956	2,152	2,529	3,006	2,829	4,407
Inventories	590	859	1,024	991	1,093	1,513	1,976	1,725	1,850	1,523
Trade Receivables	480	633	875	967	1,555	1,557	1,768	1,768	1,754	1,560
Cash Equivalents	524	199	278	398	766	1,673	2,297	2,164	1,066	1,056
Others Assets ⓘ	640	755	744	616	767	841	1,436	930	3,380	3,953
Total Assets ⓘ	4,413	5,307	6,236	6,656	8,287	9,818	12,120	11,646	12,751	14,166

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	630	499	318	745	682	1,324	1,299	1,437	1,687	2,189
PBT ⓘ	839	894	934	944	1,338	1,884	1,753	1,327	1,881	2,597
Adjustment ⓘ	-65	-4	77	130	141	123	108	129	212	-51
Changes in Working Capital ⓘ	3	-187	-512	-124	-564	-362	-227	206	-53	40
Tax Paid ⓘ	-147	-205	-181	-205	-234	-321	-335	-224	-353	-397
Cash Flow From Investing Activity ⓘ +	311	-362	-273	-313	-995	-1,121	-1,669	197	-866	-1,007
Capex	-167	-452	-493	-353	-267	-95	-234	-139	-100	-186
Net Investments	386	195	268	175	-448	-916	-1,123	483	-962	-691
Others ⓘ	92	-105	-48	-135	-280	-111	-312	-147	196	-130
Cash Flow From Financing Activity ⓘ +	-958	-125	-60	-276	173	-209	437	-1,711	-959	-1,037
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-26	-30	6	-0	0	0	0	0	0	0
Interest Paid ⓘ	-53	-24	-32	-28	-39	-38	-26	-70	-62	-56
Dividend Paid ⓘ	-152	-72	-179	-179	-359	-335	-418	-526	-538	-502
Others ⓘ	-727	0	145	-68	570	163	881	-1,116	-359	-478
Net Cash Flow ⓘ	-18	13	-15	156	-141	-5	67	-77	-138	145

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	20.9	22.1	15.43	15.45	21.53	24.23	18.83	12.54	15.68	18.27
ROCE (%)	21.94	21.01	18.97	17.05	20.46	23.43	17.96	13.17	15.23	19.66
Asset Turnover Ratio	0.85	0.96	0.96	0.93	0.93	0.84	0.85	0.8	0.67	0.67
PAT to CFO Conversion(x)	0.9	0.57	0.44	0.93	0.54	0.79	0.84	1.27	1.08	1.05
Working Capital Days
Receivable Days	40	44	50	56	66	75	65	68	79	67
Inventory Days	53	57	62	62	54	63	69	71	80	68
Payable Days	116	146	158	144	128	140	125	119	232	245

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Alkem Laboratories Ltd FAQs

The current trading price of Alkem Laboratories on 17-Apr-2026 16:59 is ₹5,583.7.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of Alkem Laboratories stood at ₹66,761.5 Cr

The latest P/E ratio of Alkem Laboratories as of 16-Apr-2026 is 30.43.

The latest P/B ratio of Alkem Laboratories as of 16-Apr-2026 is 4.67.

The 52-week high of Alkem Laboratories is ₹5,933 and the 52-week low is ₹4,716.8.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Alkem Laboratories is ₹9,450 ( Cr.) .

About Alkem Laboratories Ltd

Alkem Laboratories is one of India’s largest generic and specialty pharmaceutical company. Also, it has consistently been ranked amongst the top ten pharmaceutical companies in India. Its portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, its dominance in anti-infective segment has remained unchallenged. Some part of its revenue is generated via offshore sales. The company has manufacturing facilities at multiple locations in India and the United States of America. Its upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries.

Business area of the company

The company is one of India’s foremost global pharmaceutical company. The company is engaged in the development, manufacture and marketing of pharmaceuticals with operational footprints across different countries. In India, it has a formidable presence in several therapy segments and consistently features amongst the top ten pharmaceutical companies. Steered by its industry experience of over four decades, it offers high-quality branded generics, generic drugs, active pharmaceutical ingredients and nutraceuticals.

Awards and Recognition

2016:

Won the 'HR Tech Award for Best use of Technology in Human Resources' by World HRD Congress.
Won the Best Demand Planning and Forecasting Company - Pharmaceutical by ISCM's - SCMPro's in Demand Planning and Forecasting Forum Awards 2016.
Alkem-Pentacare division won the most enterprising company in leveraging technology in use of Mobile Applications by DigiPharmaX.
Brand 'Pan' received ‘Brand of the Year' award in sub-chronic category at AWACS Awards, 2016.
Alkem won the Guinness World Record for creating largest Blister Pack Mosiac at RSSDI Hyderabad.

2017:

Alkem Corporate Video won the 1st runners up award in the Best Corporate Film for driving Employee Engagement initiatives in the Mega Corporate Film Festival and Awards held in Mumbai.
Received the Best Stand-out IR award 2017 by IR Society India in association with KPMG and Bloomberg.
Won the People Matters league Awards - Learning & Development 2017 - Best in Cultural Transformation in Mumbai.
Won the Guinness world Records for creating largest Bindi Mosiac at RSSDI Bhubaneswar.
Won the Rising Digital Star of the Year for various digital initiatives by DigiPharmaX Awards 2017.

2018:

Best Innovative CSR Project at CSR Summit & Awards 2018.
Brand ‘Clavam’ received Brand of the Year 2018 Award at AWACS Awards for marketing excellence.
Business Excellence Award 2018 for Best Range of ICU Products, Pharma and Health Care Summit organized by CIMS (Current Index of Medical Specialties).

2019:

Express Pharma Excellence Award at Pharma CXO Summit 2011.
Best Use of Technology in Sales Hiring by Global Eminence Digital Awards sponsored by AQUILAA.

2020:

CIO Conclave and Awards 2020 in the category ‘Best IT Team of the year’.
Alkem Laboratories as Great Place to Work-Certified organization in the large organization category across industries.
India's Best Workplaces in Biotechnology & Pharmaceuticals.

Milestones

1973: Inception of Alkem Laboratories.
1978: First manufacturing unit was established at Taloja near Mumbai.
1992: Second manufacturing facility established at Mandva, Gujarat which was converted into an API facility in 2005.
2003: First research and development facility established at Taloja.
2006: Taxim became India’s first anti-infective drug to surpass annual sales figure of ` 1,000 million in the domestic market.
2007: Filed the first ANDA in the United States for the drug Amlodipine.
2009: Received the first ANDA approval in the United States for the drug Amlodipine.
2009: Acquired Pharmacor Pty. Ltd., a generic pharmaceutical company in Australia.
2010: Acquired Ascend Laboratories, pharmaceutical company in the United States.
2011: Acquired Enzene, a company engaged in the development of biosimilars in India.
2012: Acquired an API manufacturing facility in the United States.
2014: Acquired the ‘Clindac-A’ brand in India from Galderma S.A.
2014: Clavam surpassed Rs 2,000 million domestic sales figure.
2015: Acquired a formulation manufacturing facility in the United States.
2015: Successfully completed Initial Public Offering (IPO).
2018: Revenue from the US market crossed $ 200 million in annual sales.
2019: Crossed the revenue milestone of $1 billion.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Alkem Laboratories Ltd (ALKEM) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Alkem Laboratories Share Price